A double-blind, randomised, parallel-group multicentre phase 3b study.
Subjects with moderate-to-severe psoriasis and significant nail involvement (N=198) were randomised (1:1:1) to subcutaneous Cosentyx 300 mg or 150 mg, or placebo up to Week 128. Primary endpoint was NAPSI change from baseline at Week 16. At Week 16, all subjects receiving placebo were re-randomised 1:1 to Cosentyx 300 mg or 150 mg.
NAPSI: Nail Psoriasis Severity Index.